N/A
N=72
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
Hemiparesis · Stroke
Bottom Line
View on ClinicalTrials.gov: NCT01662960 ↗Enrolled (actual)
72
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Upper Extremity Fugl-Meyer — 43.8; 21.4; 42.8; 21.5 score on a scale — p=.443
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mirror therapy (Behavioral); Divider therapy (Behavioral)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Albert Einstein Healthcare Network
- Primary completion
- Feb 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Upper Extremity Fugl-Meyer |
43.8; 21.4; 42.8; 21.5 | .443 |
| PRIMARY Action Research Arm Test |
39.9; 7.1; 39.1; 7.7 | .80 |
| PRIMARY Rivermead Assessment of Somatosensory Performance |
0.76; 0.52; 0.79; 0.60 | .93 |
| PRIMARY Virtual-reality Assessment of Navigation |
— | — |
| SECONDARY Stroke Impact Scale |
221.0; 231.6; 237.8; 217.0 | .28 |
| SECONDARY Wolf Motor Function Test |
50.0; 22.3; 50.4; 24.7 | .86 |
Summary
The purpose of the study is to determine whether an existing treatment for problems that participants have with making movements after a stroke can be performed at home.
Eligibility Criteria
Inclusion Criteria
- 6 months or more post-stroke
- upper extremity Fugl-Meyer score between 10 and 50
- no longer participating in upper-extremity physical or occupational therapy
- sufficient comprehension ability to understand instructions
Exclusion Criteria
- previous head trauma, psychiatric illness or chronic exposure to medications that might be expected to have lasting consequences for the central nervous system (e.g., haloperidol, dopaminergics)
- dementia
Data sourced from ClinicalTrials.gov (NCT01662960). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.